Milla’s Athenex Pharmaceuticals division launches generic magnesium sulfate in water for injection

Magnesium sulfate injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia.
Sandra Levy
Senior Editor

Milla Pharmaceuticals, a subsidiary of the Alter Pharma Group, announced that its partner, Athenex Pharmaceutical division, has started to commercialize generic magnesium sulfate in water for injection, 2 gm/50 ml (40 mg/ml), 4 gram/100 ml (40 mg/ml) and 4 gram/50 ml (80 mg/ml), in non-PVC, single-patient use containers.

Magnesium sulfate injection is indicated for preventing and controlling seizures in preeclampsia and eclampsia. When used judiciously, it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant, the company said.

The company also noted that magnesium sulfate injection is currently on the ASHP drug shortage list of essential medications. This latest launch of magnesium sulfate injection will help reduce the recent supply issues for the product experienced in the United States.

[Read more: Dr. Reddy's to acquire generic injectables portfolio]

“It’s very exciting to see another of our products hit the U.S. market, and less than 2 years after our launch of sodium acetate injection, and less than three years after the launch of our generic injectable acetaminophen (Paracetamol IV),” said Erik Lazarich, president of the U.S. operations of the Alter Pharma Group and director of Milla Pharmaceuticals. “Moreover, this is another product considered to be in shortage. By launching our magnesium sulfate injection and providing this high-quality generic equivalent to patients in need, we directly contribute to the realization of our ambition to make affordable medicines available to all, whether that is in the EU or the U.S.”

[Read more: Hikma to launch 4 generics in Canada]

“We are very pleased to launch this important product with our partner Milla Pharmaceuticals. This product is consistently on the FDA’s Shortage List and this launch will enable the product to be utilized by patients that desperately need the drug. We look forward to additional new launches with Milla Pharmaceuticals in the future,” said Jeffrey Yordon, president of APD.


This ad will auto-close in 10 seconds